Added to YB: 2026-02-05
Pitch date: 2026-02-03
TBPH [bullish]
Theravance Biopharma, Inc.
-19.54%
current return
Author Info
No bio for this author
Company Info
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Market Cap
$687.6M
Pitch Price
$20.01
Price Target
30.00 (+86%)
Dividend
N/A
EV/EBITDA
-12.82
P/E
23.38
EV/Sales
4.97
Sector
Pharmaceuticals
Category
value
$TBPH Long
TBPH: Biotech w/ $300M cash, $250M royalty value vs $950M mkt cap. CYPRESS Ph3 trial readout Feb targeting MSA patients w/ preserved autonomic function after failed broader nOH study. Ampreloxetine NET inhibitor mechanistically suited for MSA vs PD/PAF. Sum-of-parts floor ~$16/share, ~100% upside to $30 on positive data assuming 1.5x multiple on $700M peak sales. March 2026 options attractive risk/reward.
Read full article (8 min)